At the end of June, the deadline for the introduction of the guidance document for centralized drug procurement in public hospitals of the Health and Family Planning Commission is gradually approaching。Great Wisdom news Agency was informed that the centralized drug procurement method will undergo subversive changes, from the restrictions of the public hospital bidding catalog to the establishment of a price negotiation mechanism, from the introduction of price leverage to change drug price management to explore the medical insurance benchmark price quota payment method, the comment draft beyond the traditional changes gradually manifested。

        At the end of last month, The General Office of the State Council issued a notice on deepening the key tasks of medical reform in 2014, which stipulates that by the end of June, the health and Family Planning Commission and other departments should complete the guidance document on centralized drug procurement in public hospitals。In the past two weeks, the Health and Family Planning Commission has been intensively discussing the draft, and a source told the Great Wisdom News agency that an internal symposium was held in Qingdao on Monday and "there will be another meeting this weekend to continue the discussion."。

        An industry veteran said that although on the surface, the procurement method has become more and more inclined to the dominant position of hospitals, and the bidding catalog has become a general trend, the nature of centralized bidding has not changed, "it is still accelerating import substitution and protecting domestic large pharmaceutical companies."。

Subversion of tradition: "Anhui figure" reappearance

    "Provinces develop the" Public hospital drug procurement catalogue ", specific to the variety, dosage form, specifications ", which has become the most eye-catching words in the draft for comments。As soon as the news came out, the industry was in an uproar, and they believed that the subversive provisions restricting the bidding catalogue were actually increasing the space for rent-seeking。The frontline people of pharmaceutical companies are also like ants on the hot pot overnight, worrying that their own varieties are excluded from the catalog, and sales can not be on the quantity。

        In fact, the restricted bidding list has already emerged in the pharmaceutical bidding in Anhui province。The scope of the new round of drug bidding in the province has "subverted" the traditional catalogue and is limited to 1,118 basic drugs selected by the province for public hospitals. Previously, insiders of the provincial health department revealed that the main purpose of restricting the bidding catalogue is to control medical costs。

        Now, the "Anhui figure" again reflects that the Health and Family Planning Commission seems to want to promote it to the whole country, the provinces will strictly control the bidding catalog, which also means that not all non-basic drugs will be included in the scope of the bidding, some unusual supplies or face the risk of being kicked out。

        An insider analysis of North China pharmaceutical companies, "two bids in one" is a trend, restricting the bidding catalog actually restricts some abnormal specifications to enter the bidding, because some enterprises by declaring abnormal specifications, new dosage forms and other ways to bypass the bidding limit price in disguise。He believes that the focus of the bidding catalogue is to highlight the core position of basic drugs and medical insurance products。

        The above-mentioned North China pharmaceutical company further said that "the restricted bidding catalogue is certain", the varieties outside the catalogue can not be bidding, so they can not enter the hospital, even if there is a record procurement, it is very small, "therefore, crossing this threshold is the key"。A person from a South China pharmaceutical company admitted that the focus of many companies is on non-basic drugs, so the restriction of the catalog adds a threshold for pharmaceutical companies to access。"However, we are more concerned about the proportion of restricted use of out-of-catalog varieties, which depends on the attitude of the provinces."。

All the same: accelerating import substitution

    “其实，The nature of centralized bidding to protect large domestic enterprises has not changed."，The above-mentioned pharmaceutical companies in North China pointed out，On the one hand, the restrictions of the bidding catalogue have raised the threshold of some non-medical insurance products，Most of these non-medical insurance products are foreign-funded products with high prices and high rebates.On the other hand, some small varieties produced by small enterprises are also difficult to get approval。

        At the same time, the "price negotiation mechanism" mentioned in the draft for comments also points to individual pricing, original research and other varieties。The draft clearly stipulates that for patented drugs, exclusive varieties, separate pricing, imported joint venture drugs, anti-tumor adjuvant drugs, antibiotics, cardio-cerebrovascular drugs and other drugs with high prices, difficult to bid, and large sales, local medical insurance agencies shall negotiate with drug suppliers to reduce drug prices。Individual varieties are also allowed to be negotiated at the national level on a trial basis。

        In fact, at the end of last year, the health and Family Planning Commission began to establish a price negotiation mechanism, and plans to select 17 national health reform pilot areas to negotiate, and then reduce the inflated prices of these drugs from the country。Provinces such as Zhejiang and Jiangsu have included high-priced anti-tumor drugs in the negotiation mechanism。

        The draft also requires provinces to explore other procurement methods, such as hospitals to develop drug purchase lists, reasonably determine the total amount of transactions, directly entrust or form joint drug suppliers, package procurement according to the drug list, or explore medical insurance benchmark price quota payment methods。

    "No matter how the procurement method changes, the bidding model of the double envelope has not changed, the purpose of the bidding price reduction of the Health and Family Planning Commission will not change", a practitioner of eastern China pharmaceutical companies for many years said that supporting large enterprises and accelerating import substitution is the future trend。Similarly, the above-mentioned people of South China pharmaceutical companies also expressed the same view, and the gradual elimination of the "super national treatment" of foreign capital was also revealed in the consultation draft。

Non-basic drug bidding process 'stalled'

        The "emergence" of this procurement document may once again disrupt the rhythm of drug bidding。

        The aforementioned South China pharmaceutical company told the Great Wisdom news Agency，The document is only for comment，However, there are no regulations on the formulation department of the bidding list and whether the varieties outside the list have access to the hospital，next，The bidding of non-basic drugs should be in the "wait and see" stage，"I am afraid that some provinces that have prepared tender documents will have to overturn everything and start again."。

        Another North China pharmaceutical company said that not only the launch of this document, the provinces are currently busy with their own low-cost drug catalog, so the overall non-basic drug bidding process will be delayed。As of today, in addition to Jilin has completed all the work of basic and non-basic drug bidding, Hunan has also completed the qualification review, Anhui, Jiangxi and other provinces are in a state of suspension。

Note: The information comes from the Internet